20th June 2023
Our CTO, Omar Qureshi, presented our Human Immuno-oncology platform at Immuno-oncology Summit Europe 2023
22nd May 2023
The Celentyx team presented data from our inflammation platform on the impact of ruxolitinib upon IL-6 signaling at #slaseurope2023
February 2023
Celentyx invited to join Department of International Trade mission to Barcelona
6th June 2022
Celentyx CEO Professor Nicholas Barnes and CTO Dr Omar Qureshi to present at Antibody Engineering & Therapeutics Europe, Amsterdam, 7-9 June 2022
https://informaconnect.com/antibody-engineering-europe/
19th October 2021
Celentyx CTO, Omar Qureshi presents at ELRIG Drug Discovery 2021
1st January 2021
Celentyx in collaboration with the Universities of Birmingham and Warwick are developing assays for COVID-19 drug discovery and monitoring. The project is co-funded by the UK’s innovation agency, Innovate UK.
28th November 2019
Omar Qureshi to present at British Society for Immunology Congress 2019
Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade using pembrolizumab under acute, chronic, and exhaustion-like conditions of T-cell stimulation
https://www.immunology.org/events/british-society-for-immunology-congress-2019
12th November 2019
Celentyx CEO Professor Nicholas Barnes is awarded the prestigious 2019 BMA Foundation for Medical Research J Moulton Award joint with Dr Golam Khandaker of the University of Cambridge in recognition of their work in neuroinflammation in psychiatric disorders
21st March 2019
Celentyx to present latest work on high-content imaging of myelin phagocytosis by human monocyte-derived microglia at the ELRIG Research & Innovation meeting at Homerton College, Cambridge on 2-3 April 2019
https://elrig.org/portfolio/2019-research-innovation/
5th February 2019
Celentyx to attend Immune-Oncology 360°, New York USA, February 6-8, 2019
https://theconferenceforum.org/conferences/immuno-oncology-360/overview/
4th February 2019
We are recruiting! We are looking for a highly-motivated and experienced Senior Business Development Executive to join Celentyx
Further information...
12th November 2018
Celentyx to present at Pharmaceutical Flow Cytometry & Imaging 2018, GSK Stevenage UK, 14-15 Nov 2018
https://elrig.org/portfolio/fc2018/
8th October 2018
Celentyx to present latest immuno-oncology, neuroinflammation and fibrosis assay data at ELRIG Drug Discovery 2018, London UK, 9-10 Oct 2018
https://elrig.org/portfolio/dd2018/
8th October 2018
We are recruiting! We are currently looking for a talented and highly-motivated senior scientist to join Celentyx
Further information...
4th October 2018
Celentyx attends BioForward, Birmingham UK
https://www.bioforward.co.uk
4-7th June 2018
Celentyx attends BIO 2018 in Boston as part of the Midlands Engine visit
1st March 2018
Celentyx delighted to announce appointment of Dr Omar Qureshi as VP, Scientific Operations
26th February 2018
Celentyx to present at AACR Annual Meeting 2018, Chicago USA, 14-18 April 2018
Poster 622 / 16: Differential impact of pembrolizumab and ipilimumab on IFNgamma and IL-10 production from in-vitro monocyte-derived DC and T cell co-cultures
Further information...
1st March 2017
Celentyx VP Immunology & Oncology, Dr Matthew Baker to present at Next Gen Immuno-Oncology Congress, London UK, 13-14 March 2017
Further information...
5th January 2017
Immcell and Celentyx collaboration demonstrates benefit of immune-modulatory drug for immuno-compromised individuals and patients with viral infection http://dx.doi.org/10.1016/j.intimp.2016.11.023
Further information...
1st December 2016
We are recruiting! We are currently looking for a talented and highly-motivated individual to join Celentyx as VP, Scientific Operations and lead our in vitro analytical team
Further information...
1st December 2016
Dr Matthew Baker Joins Celentyx Ltd as VP Immunology & Oncology
Further information...
20th October 2016
Celentyx CSO, Professor John Gordon, appointed to the ESF College of Expert Reviewers
8th June 2016
Celentyx will be visiting current and prospective clients in the Boston area from 11-15th July - do let us know if you are in the area and would like to arrange a visit - catherine.brady@celentyx.com
19th May 2016
Celentyx are recruiting! We are currently looking for a talented and highly-motivated postdoctoral scientist to join our in vitro analytical team
Further information...
1st April 2016
Celentyx CSO, Professor John Gordon, appointed Regional Editor-in-Chief for the journal Integrative Molecular Medicine
http://www.oatext.com/IntegrativeMolecularMedicine.php#Editorial_Board
30th October 2015
Celentyx CSO, Professor John Gordon, to present at International Hematology Club meeting in Paris, France, 6-7 November 2015
2nd September 2015
Congratulations to our CEO, Professor Nicholas Barnes, principal author of the most highly cited research paper ever from any research institution in Birmingham with over 2000 citations.
Further information...
28th July 2015
We are delighted to announce that Professor Nicholas Barnes, Principal Founder of Celentyx Ltd, has been conferred as Honorary Professor within the Department of Pharmacology and Therapeutics, Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne in recognition of his outstanding and distinguished academic service in pharmacology. The University of Melbourne is ranked 33rd in the World (The Times World University Rankings)
http://pharmacology.unimelb.edu.au
27th January 2015
Celentyx seeks to recruit CBO
7th August 2014
Celentyx CSO, Professor John Gordon, appointed to editorial board of MOJ Immunology http://medcraveonline.com/MOJI/editorial-board
16th February 2014
Celentyx expands the team with 2 research positions available
13th February 2013
Celentyx introduces electrophysiological recording from human immune cells
17th October 2012
Professor Nicholas Barnes, Prinicipal Founder of Celentyx Ltd, is conferred as an Honorary Professor at the University of Siena for his contribution to Biotechnology
19th August 2011
Celentyx founders Professor John Gordon & Professor Nicholas Barnes identify potential of modified Ecstasy as potent blood cancer treatment
Download pdf
15th October 2010
Professor John Gordon to present Raine Visiting Professor Lecture entitled:
The Emergence of ‘Neuro-Immuno-Pharmacology’: Lymphoma Gets Nervous
Further information...
28th September 2010
Dr John Curnow joins Celentyx as Principal Scientist.
Further information...
8th December 2009
Alan Boyd appointed Honorary Professor at the University of Birmingham Medical School.
Further information...
24th August 2009
Celentyx enters into agreement with Meiji Seika Kaisha, Ltd to discover new development paths for Meiji drug candidates using Celentyx’s Novel Clinical Indication Profiling™
Further information...
8th July 2009
Celentyx announces Immuno-Profiling™ collaboration with natural products drug company Hypha Discovery.
Further information...
11th May 2009
Ann Hayes Joins Celentyx Ltd as Chairman of the Board.
Further information...
10th December 2008
Celentyx announces continued collaboration with AMRI.
Further information...
27th October 2008
Celentyx announces collaboration with Alfama Inc.
30th September 2008
Celentyx and AMRI to present data at British Pharmacological Society Winter Meeting 2008
Brighton, UK, 16-18 December, 2008
18th July 2008
Celentyx and AMRI present data at Serotonin Club Meeting 2008 in Oxford, UK
3rd January 2008
Celentyx announces collaboration with Schering-Plough
Further information...
12th December 2007
Celentyx secures major funding boost
Further information...
2nd March 2007
Official launch of Celentyx Ltd
Further information...
26th January 2007
Ethical permission granted to Celentyx Ltd for use of human blood cells
13th December 2006
Award of TTF grant to expand operations
17th October 2006
Celentyx Ltd awarded DTI R&D grant
2nd October 2006
First NCIP™ contract with North American pharmaceutical
company
Our CTO, Omar Qureshi, presented our Human Immuno-oncology platform at Immuno-oncology Summit Europe 2023
22nd May 2023
The Celentyx team presented data from our inflammation platform on the impact of ruxolitinib upon IL-6 signaling at #slaseurope2023
February 2023
Celentyx invited to join Department of International Trade mission to Barcelona
6th June 2022
Celentyx CEO Professor Nicholas Barnes and CTO Dr Omar Qureshi to present at Antibody Engineering & Therapeutics Europe, Amsterdam, 7-9 June 2022
https://informaconnect.com/antibody-engineering-europe/
19th October 2021
Celentyx CTO, Omar Qureshi presents at ELRIG Drug Discovery 2021
1st January 2021
Celentyx in collaboration with the Universities of Birmingham and Warwick are developing assays for COVID-19 drug discovery and monitoring. The project is co-funded by the UK’s innovation agency, Innovate UK.
28th November 2019
Omar Qureshi to present at British Society for Immunology Congress 2019
Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade using pembrolizumab under acute, chronic, and exhaustion-like conditions of T-cell stimulation
https://www.immunology.org/events/british-society-for-immunology-congress-2019
12th November 2019
Celentyx CEO Professor Nicholas Barnes is awarded the prestigious 2019 BMA Foundation for Medical Research J Moulton Award joint with Dr Golam Khandaker of the University of Cambridge in recognition of their work in neuroinflammation in psychiatric disorders
21st March 2019
Celentyx to present latest work on high-content imaging of myelin phagocytosis by human monocyte-derived microglia at the ELRIG Research & Innovation meeting at Homerton College, Cambridge on 2-3 April 2019
https://elrig.org/portfolio/2019-research-innovation/
5th February 2019
Celentyx to attend Immune-Oncology 360°, New York USA, February 6-8, 2019
https://theconferenceforum.org/conferences/immuno-oncology-360/overview/
4th February 2019
We are recruiting! We are looking for a highly-motivated and experienced Senior Business Development Executive to join Celentyx
Further information...
12th November 2018
Celentyx to present at Pharmaceutical Flow Cytometry & Imaging 2018, GSK Stevenage UK, 14-15 Nov 2018
https://elrig.org/portfolio/fc2018/
8th October 2018
Celentyx to present latest immuno-oncology, neuroinflammation and fibrosis assay data at ELRIG Drug Discovery 2018, London UK, 9-10 Oct 2018
https://elrig.org/portfolio/dd2018/
8th October 2018
We are recruiting! We are currently looking for a talented and highly-motivated senior scientist to join Celentyx
Further information...
4th October 2018
Celentyx attends BioForward, Birmingham UK
https://www.bioforward.co.uk
4-7th June 2018
Celentyx attends BIO 2018 in Boston as part of the Midlands Engine visit
1st March 2018
Celentyx delighted to announce appointment of Dr Omar Qureshi as VP, Scientific Operations
26th February 2018
Celentyx to present at AACR Annual Meeting 2018, Chicago USA, 14-18 April 2018
Poster 622 / 16: Differential impact of pembrolizumab and ipilimumab on IFNgamma and IL-10 production from in-vitro monocyte-derived DC and T cell co-cultures
Further information...
1st March 2017
Celentyx VP Immunology & Oncology, Dr Matthew Baker to present at Next Gen Immuno-Oncology Congress, London UK, 13-14 March 2017
Further information...
5th January 2017
Immcell and Celentyx collaboration demonstrates benefit of immune-modulatory drug for immuno-compromised individuals and patients with viral infection http://dx.doi.org/10.1016/j.intimp.2016.11.023
Further information...
1st December 2016
We are recruiting! We are currently looking for a talented and highly-motivated individual to join Celentyx as VP, Scientific Operations and lead our in vitro analytical team
Further information...
1st December 2016
Dr Matthew Baker Joins Celentyx Ltd as VP Immunology & Oncology
Further information...
20th October 2016
Celentyx CSO, Professor John Gordon, appointed to the ESF College of Expert Reviewers
8th June 2016
Celentyx will be visiting current and prospective clients in the Boston area from 11-15th July - do let us know if you are in the area and would like to arrange a visit - catherine.brady@celentyx.com
19th May 2016
Celentyx are recruiting! We are currently looking for a talented and highly-motivated postdoctoral scientist to join our in vitro analytical team
Further information...
1st April 2016
Celentyx CSO, Professor John Gordon, appointed Regional Editor-in-Chief for the journal Integrative Molecular Medicine
http://www.oatext.com/IntegrativeMolecularMedicine.php#Editorial_Board
30th October 2015
Celentyx CSO, Professor John Gordon, to present at International Hematology Club meeting in Paris, France, 6-7 November 2015
2nd September 2015
Congratulations to our CEO, Professor Nicholas Barnes, principal author of the most highly cited research paper ever from any research institution in Birmingham with over 2000 citations.
Further information...
28th July 2015
We are delighted to announce that Professor Nicholas Barnes, Principal Founder of Celentyx Ltd, has been conferred as Honorary Professor within the Department of Pharmacology and Therapeutics, Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne in recognition of his outstanding and distinguished academic service in pharmacology. The University of Melbourne is ranked 33rd in the World (The Times World University Rankings)
http://pharmacology.unimelb.edu.au
27th January 2015
Celentyx seeks to recruit CBO
7th August 2014
Celentyx CSO, Professor John Gordon, appointed to editorial board of MOJ Immunology http://medcraveonline.com/MOJI/editorial-board
16th February 2014
Celentyx expands the team with 2 research positions available
13th February 2013
Celentyx introduces electrophysiological recording from human immune cells
17th October 2012
Professor Nicholas Barnes, Prinicipal Founder of Celentyx Ltd, is conferred as an Honorary Professor at the University of Siena for his contribution to Biotechnology
19th August 2011
Celentyx founders Professor John Gordon & Professor Nicholas Barnes identify potential of modified Ecstasy as potent blood cancer treatment
Download pdf
15th October 2010
Professor John Gordon to present Raine Visiting Professor Lecture entitled:
The Emergence of ‘Neuro-Immuno-Pharmacology’: Lymphoma Gets Nervous
Further information...
28th September 2010
Dr John Curnow joins Celentyx as Principal Scientist.
Further information...
8th December 2009
Alan Boyd appointed Honorary Professor at the University of Birmingham Medical School.
Further information...
24th August 2009
Celentyx enters into agreement with Meiji Seika Kaisha, Ltd to discover new development paths for Meiji drug candidates using Celentyx’s Novel Clinical Indication Profiling™
Further information...
8th July 2009
Celentyx announces Immuno-Profiling™ collaboration with natural products drug company Hypha Discovery.
Further information...
11th May 2009
Ann Hayes Joins Celentyx Ltd as Chairman of the Board.
Further information...
10th December 2008
Celentyx announces continued collaboration with AMRI.
Further information...
27th October 2008
Celentyx announces collaboration with Alfama Inc.
30th September 2008
Celentyx and AMRI to present data at British Pharmacological Society Winter Meeting 2008
Brighton, UK, 16-18 December, 2008
18th July 2008
Celentyx and AMRI present data at Serotonin Club Meeting 2008 in Oxford, UK
3rd January 2008
Celentyx announces collaboration with Schering-Plough
Further information...
12th December 2007
Celentyx secures major funding boost
Further information...
2nd March 2007
Official launch of Celentyx Ltd
Further information...
26th January 2007
Ethical permission granted to Celentyx Ltd for use of human blood cells
13th December 2006
Award of TTF grant to expand operations
17th October 2006
Celentyx Ltd awarded DTI R&D grant
2nd October 2006
First NCIP™ contract with North American pharmaceutical
company